세계의 체외진단(IVD) 검사용 재택 및 자택 채취 시장(2025-2030년)

The convenience revolution in healthcare has arrived-and diagnostics are at the center of it. "The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025-2030" provides a comprehensive analysis of one of the fastest-evolving sectors of the diagnostics industry. Covering both self-administered over-the-counter (OTC) tests and home collection kits analyzed in central laboratories, this Kalorama Information report examines the technologies, market forces, and consumer behaviors transforming how patients engage with testing and care.

For diagnostic developers, investors, and healthcare strategists, "The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025-2030" provides the essential insight needed to understand how home diagnostics are moving beyond niche applications to become a core component of modern healthcare delivery-and a key driver of the global IVD market's future growth.

Building on the momentum sparked by the COVID-19 pandemic, the report explores how growing public confidence in self-testing is reshaping the landscape of infectious disease detection, chronic disease management, oncology, genetic testing, and wellness screening. While glucose monitoring and pregnancy testing continue to anchor the category, innovations in non-invasive sampling methods-from saliva and urine to breath analysis-are enabling a broader range of tests to move from clinic to home.

The global Home IVD testing market is segmented into several broad areas, including:

• Genetic
• Glucose/ HbA1c
• Infectious disease
• Other areas
  • Pregnancy and Fertility
  • Coagulation
  • Fecal Occult Blood
  • Cholesterol
  • Drugs of Abuse

Each market segment includes a detailed analysis of regulatory trends, clinical practices, and recent product approvals, along with 2025 sales data and forecasts through 2030 across major world regions, including the United States, EMEA, Asia Pacific, and the Rest of World. The study profiles key market leaders and emerging competitors, evaluating how technological advances, consumer acceptance, and cost considerations will drive growth and shape competition.

The report also distinguishes between the two major segments:

• At-Home IVD Tests - fully self-administered tests providing immediate results (e.g., pregnancy and glucose monitoring).
• Home Collection IVD Tests - tests where patients collect samples and send them to a laboratory for analysis (e.g., fecal occult blood, genetic, and infectious disease testing).

Scope and Methodology

Using a combination of primary interviews and secondary research, the report delivers reliable market sizing, competitive intelligence, and growth projections based on 2025 as the base year. Forecasts through 2030 include compound annual growth rates (CAGRs) and regional performance indicators.

Despite the growing demand, the report also acknowledges ongoing challenges in cost-benefit analysis, reimbursement models, and regulatory and privacy frameworks that may shape the pace of adoption.

Table of Contents

Chapter 1: Executive Summary

• Industry at a Glance
• Size and Growth of the Market
  • Figure 1-1: Global Home IVD Market by Key Segment, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
• Key Issues and Trends Affecting the Market
• Competitive Outlook
• Conclusion Highlights
• About Kalorama Information

Chapter 2: Introduction

• Home IVD Testing Overview
  • Market Segments
  • Market Evolution
  • Historical Context
  • Market Drivers
  • Key Players
• Issues and Trends
  • COVID-19 Evolution
    • Figure 2-1: Home COVID-19 Test Distribution of Sales, by Vendor, 2025 (%)
  • Reimbursement for Home Tests
  • Continuous Glucose Monitors
    • Figure 2-2: Continuous Glucose Monitor Access for Medicaid Beneficiaries Living with Diabetes: State-By-State Coverage
  • Infectious Disease
  • Cancer
  • Chronic Disease Monitoring
  • Genetic
  • Home IVD Testing Drivers and Challenges
    • Figure 2-3: Benefits and Challenges to Home Testing, 2025
  • Key Benefits of Home Testing
  • Key Challenges of Home Testing
• Genetics
  • Table 2-1: Home Genetic Laboratory Testing, Market Drivers and Barriers
• Home Collection

Chapter 3: At-Home IVD Tests

• Introduction
  • Diabetes
    • Table 3-1: Selected Glucose At-Home Testing Meter Innovations
  • Pregnancy and Fertility
  • Infectious Disease
  • HIV
  • COVID-19 & Flu
    • Table 3-2: Selected Molecular COVID-19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
    • Table 3-3: Selected Antigen COVID- 19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
  • Coagulation
  • Fecal Occult Blood
  • Cholesterol
  • Drugs of Abuse
• At-Home IVD Test Market by Test Type
  • Table 3-4: Global At-Home IVD Market, by Test Type, 2025 ($ billion) [Glucose, Infectious Disease, Other]
  • Figure 3-1: Global At-Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19+, Drug of Abuse, FOB, Glucose, HIV, Other Infections, Pregnancy & Fertility, Other]
• At-Home IVD Tests Market by Sample Type
  • Table 3-5: Global At-Home IVD Market, by Sample Type, 2025 ($ billion) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
  • Figure 3-2: Global At-Home IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
  • Figure 3-3: Year-over-Year Growth for At-Home IVD Markets, '23-24 & '24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Glucose, HIV, Infectious Disease, Pregnancy & Fertility, Other]
  • Blood Samples
    • Figure 3-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Coagulation, Glucose, Other]
  • Interstitial Fluid Samples
  • Urine Samples
    • Figure 3-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Drugs of Abuse, Infectious Disease, Pregnancy, Other]
  • Oral/Saliva Samples
    • Figure 3-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, HIV, Other]
  • Nasal Samples
    • Figure 3-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
  • Stool Samples
    • Figure 3-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Other]
  • Other

Chapter 4: Home Collection IVD Tests

• Introduction
  • Pregnancy and Fertility
  • Infectious Disease
  • HIV
  • HPV and Other STDs
  • Hepatitis
  • COVID-19
  • COVID-19 & Flu
  • Fecal Occult Blood
  • Cholesterol
  • Genetics
  • Other
• Home Collection IVD Test Market by Test Type
  • Table 4-1: Global Home Collection IVD Market, by Test Type, 2025 ($ billion) [Genetics, Infectious Disease, Other Areas]
  • Figure 4-1: Global Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19, Drug of Abuse, FOB, Glucose, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other]
  • Privacy Genetic Testing
• Home Collection Tests Market by Sample Type
  • Table 4-2: Global Home Collection IVD Market, by Sample Type, 2025 ($ billion) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
  • Figure 4-2: Global Home Collection IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
  • Figure 4-3: Year-over-Year Growth for Home Collection IVD Markets, '23-24 and '24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Genetic, HbA1c, HIV, Infectious Disease, Pregnancy & Fertility, Other]
  • Blood Samples
    • Figure 4-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Fertility, Genetic, Glucose/HbA1c, Infectious Disease - STD Blood Spot, Tumor Marker - PSA Blood Spot, Other - Hormone]
  • Urine Samples
    • Figure 4-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Infectious Disease - STD, Pregnancy/Fertility, Other - Heavy Metals, Hormone, Nutrition]
  • Oral/Saliva Samples
    • Figure 4-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, Fertility, Genetic, HIV, Other - Hormone, Nutrition, Medication Match]
  • Nasal Samples
    • Figure 4-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
  • Stool Samples
    • Figure 4-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Infectious Disease - Pathogen ID, Other - Heavy Metals]
  • Other

Chapter 5: Market Participants

• 23andMe, Inc
  • Table 5-1: 23andMe Corporate Summary
  • Company Overview
    • Table 5-2: 23andMe Genetic Tests with FDA Marketing Authorization
• Abbott Diagnostics
  • Table 5-3: Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-4: Abbott Revenues, 2020-2024 ($ million)
• Abingdon Health Ltd.
  • Table 5-5: Abingdon Health Corporate Summary
  • Company Overview
• ACON Laboratories, Inc.
  • Table 5-6: ACON Laboratories Corporate Summary
  • Company Overview
• ARKRAY, Inc.
  • Table 5-7: ARKRAY Corporate Summary
  • Company Overview
• Ascensia Diabetes Care Holdings AG
  • Table 5-8: Ascensia Diabetes Care Corporate Summary
  • Company Overview
• Atomo Diagnostics
  • Table 5-9: Atomo Corporate Summary
  • Company Overview
• Becton Dickinson
  • Table 5-10: Becton Dickinson Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-11: BD Corporation Revenue, 2020-2024 ($ billion)
• binx health
  • Table 5-12: binx health Corporate Summary
  • Company Overview
• Biomerica, Inc.
  • Table 5-13: Biomerica Corporate Summary
  • Company Overview
  • Company Financials
    • Table 5-14: Biomerica Corporation Revenue, 2020-2024 ($ million)
• Biosynex SA
  • Table 5-15: Biosynex Corporate Summary
  • Company Overview
• Church & Dwight Co. Inc
  • Table 5-16: Church & Dwight Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-17: Church and Dwight Revenues, 2020-2024 ($ million)
• Color Health, Inc.
  • Table 5-18: Color Health Corporate Summary
  • Company Overview
• Dexcom, Inc.
  • Table 5-19: Dexcom Corporation Corporate Summary
  • Company Overview
• Performance Review
  • Table 5-20: Dexcom Revenues, 2020-2024 ($ million)
• EasyDNA
  • Table 5-21: EasyDNA Corporate Summary
  • Company Overview
• Everly Health
  • Table 5-22: Everly Health Corporate Summary
  • Company Overview
• Exact Sciences
  • Table 5-23: Exact Sciences Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-24: Exact Sciences Revenues (2020-2024) ($ million)
• GeneDx
  • Table 5-25: GeneDx Corporate Summary
  • Company Overview
• Helena Laboratories
  • Table 5-26: Helena Laboratories Corporate Summary
  • Company Overview
• Hemosure, Inc.
  • Table 5-27: Hemosure Corporate Summary
  • Company Overview
• Laboratory Corporation of America
  • Table 5-28: Laboratory Corporation of America Corporate Details
  • Company Overview
  • Performance Review
    • Table 5-29: Labcorp Revenue History, 2020-2024 ($ million)
• Medichecks.com Ltd.
  • Table 5-30: Medichecks Corporate Summary
  • Company Overview
• Myriad Genetics, Inc.
  • Table 5-31: Myriad Genetics Corporate Summary
• Company Overview
  • Performance Review
    • Table 5-32: Myriad Diagnostics Revenue, 2020-2024 ($ million)
• Natera
  • Table 5-33: Natera Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-34: Natera Revenue History, 2020-2024 ($ million)
• OraSure Technologies, Inc.
  • Table 5-35: OraSure Technologies Summary
  • Company Overview
  • Performance Review
    • Table 5-36: OraSure Revenues, 2020-2024 ($ million)
• Polymedco, Inc
  • Table 5-37: Polymedco Corporate Summary
  • Company Overview
• Preventis GmbH
  • Table 5-38: Preventis Corporate Summary
  • Company Overview
• Prima Lab SA
  • Table 5-39: Prima Corporate Summary
  • Company Overview
• Quest Diagnostics, Inc.
  • Table 5-40: Quest Diagnostics Corporate Details
  • Company Overview
• Performance Review
  • Table 5-41: Quest Diagnostics Revenue History, 2020-2024 ($ million)
• QuidelOrtho Corporation
  • Table 5-42: QuidelOrtho Corporate Summary
  • Company Overview
• Performance Review
  • Table 5-43: QuidelOrtho Revenues, 2020-2024 ($ million)
• Roche Diagnostic Corporation
  • Table 5-44: Roche Diagnostic Corporate Summary
  • Company Overview
• Performance Review
  • Table 5-45: Roche Diagnostics, 2020-2024 (CHF billion)
• Siemens Healthineers GmbH
  • Table 5-46: Siemens Healthineers Corporate Summary
  • Company Overview
• Performance Review
  • Table 5-47: Siemens Healthineers Revenue History, 2020-2024 (Euro million)
• Swiss Precision Diagnostics GmbH
  • Table 5-48: Swiss Precision Diagnostics Corporate Summary
  • Company Overview
• Trividia Health
  • Table 5-49: Trividia Health Corporate Summary
  • Company Overview
• VedaLab
  • Table 5-50: VedaLab Corporate Summary
  • Company Overview

Chapter 6: Market Analysis

• Market Overview
  • Figure 6-1: Global Home IVD Market, 2025-2030 ($ million) [Genetic, Infectious Disease, Other Areas]
• Market Segment by Test Type
  • Figure 6-2: Global Home IVD Market by Test Type, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
  • Figure 6-3: Global Home IVD Market, by General Test Segment, 2025 (%) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
• Glucose & HbA1c
  • Table 6-1: Estimated Global Home IVD Glucose & HbA1c Testing Market, 2025-2030 ($ million)
• Infectious Disease
  • Table 6-2: Estimated Global Home IVD Infectious Disease Testing Market, 2025-2030 ($ million)
• Genetic
  • Table 6-3: Estimated Global Home IVD Genetic Testing Market, 2025-2030 ($ million)
• Other Areas
  • Table 6-4: Estimated Global Home IVD Other Testing Market, 2025-2030 ($ million)
• Market by Distribution
• Market by Region
  • Figure 6-4: Estimated Global Home IVD Testing Market, by Region, 2023-2025 ($ million) [APAC, EMEA, United States, Rest of World]
• Competitive Analysis
  • Figure 6-5: Estimated Global Home IVD Testing Market, Top Vendor Market Share, 2025 (%)